PUMA BIOTECHNOLOGY INC (PBYI) Stock Fundamental Analysis
USA - NASDAQ:PBYI - US74587V1070 - Common Stock
5.99 USD
+1.09 (+22.24%)
6.01 USD
+0.02 (+0.33%)
PBYI gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. PBYI scores excellent on profitability, but there are some minor concerns on its financial health. PBYI is cheap, but on the other hand it scores bad on growth. This makes PBYI very considerable for value investing!
1. Profitability
1.1 Basic Checks
PBYI had positive earnings in the past year.
In the past year PBYI had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PBYI reported negative net income in multiple years.
Of the past 5 years PBYI 4 years had a positive operating cash flow.
1.2 Ratios
PBYI's Return On Assets of 24.86% is amongst the best of the industry. PBYI outperforms 97.76% of its industry peers.
PBYI has a better Return On Equity (46.27%) than 98.51% of its industry peers.
PBYI's Return On Invested Capital of 31.42% is amongst the best of the industry. PBYI outperforms 99.25% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PBYI is above the industry average of 15.48%.
The 3 year average ROIC (17.97%) for PBYI is below the current ROIC(31.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.86% | ||
| ROE | 46.27% | ||
| ROIC | 31.42% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
1.3 Margins
PBYI has a Profit Margin of 20.35%. This is amongst the best in the industry. PBYI outperforms 94.59% of its industry peers.
PBYI's Operating Margin of 19.35% is amongst the best of the industry. PBYI outperforms 94.22% of its industry peers.
PBYI's Operating Margin has improved in the last couple of years.
The Gross Margin of PBYI (72.33%) is better than 82.84% of its industry peers.
In the last couple of years the Gross Margin of PBYI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.35% | ||
| PM (TTM) | 20.35% | ||
| GM | 72.33% |
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
2. Health
2.1 Basic Checks
PBYI has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
PBYI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PBYI has been increased compared to 5 years ago.
Compared to 1 year ago, PBYI has an improved debt to assets ratio.
2.2 Solvency
PBYI has an Altman-Z score of -5.02. This is a bad value and indicates that PBYI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.02, PBYI is doing worse than 60.45% of the companies in the same industry.
The Debt to FCF ratio of PBYI is 1.01, which is an excellent value as it means it would take PBYI, only 1.01 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.01, PBYI belongs to the top of the industry, outperforming 94.22% of the companies in the same industry.
PBYI has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
PBYI's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. PBYI is outperformed by 64.18% of its industry peers.
Although PBYI does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.01 | ||
| Altman-Z | -5.02 |
ROIC/WACC3.29
WACC9.56%
2.3 Liquidity
PBYI has a Current Ratio of 1.73. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.73, PBYI is not doing good in the industry: 79.10% of the companies in the same industry are doing better.
A Quick Ratio of 1.62 indicates that PBYI should not have too much problems paying its short term obligations.
The Quick ratio of PBYI (1.62) is worse than 79.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.62 |
3. Growth
3.1 Past
PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.17%, which is quite impressive.
PBYI shows a decrease in Revenue. In the last year, the revenue decreased by -2.19%.
Measured over the past years, PBYI shows a decrease in Revenue. The Revenue has been decreasing by -3.28% on average per year.
EPS 1Y (TTM)54.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.54%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%-32.3%
3.2 Future
PBYI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -12.89% yearly.
PBYI is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.09% yearly.
EPS Next Y-17.31%
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
EPS Next 5Y-12.89%
Revenue Next Year-3.32%
Revenue Next 2Y-3.85%
Revenue Next 3Y-2.82%
Revenue Next 5Y-1.09%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PBYI is valuated reasonably with a Price/Earnings ratio of 8.09.
Based on the Price/Earnings ratio, PBYI is valued cheaper than 98.13% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.06, PBYI is valued rather cheaply.
A Price/Forward Earnings ratio of 18.18 indicates a rather expensive valuation of PBYI.
Based on the Price/Forward Earnings ratio, PBYI is valued cheaper than 93.84% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 32.73, PBYI is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.09 | ||
| Fwd PE | 18.18 |
4.2 Price Multiples
PBYI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PBYI is cheaper than 98.88% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PBYI indicates a rather cheap valuation: PBYI is cheaper than 99.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.82 | ||
| EV/EBITDA | 3.65 |
4.3 Compensation for Growth
PBYI has an outstanding profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as PBYI's earnings are expected to decrease with -17.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
5. Dividend
5.1 Amount
No dividends for PBYI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.99
+1.09 (+22.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners68.37%
Inst Owner Change-2.98%
Ins Owners15.13%
Ins Owner Change0.07%
Market Cap301.72M
Revenue(TTM)230.47M
Net Income(TTM)48.45M
Analysts42.86
Price Target4.42 (-26.21%)
Short Float %7.87%
Short Ratio5.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)204.35%
Min EPS beat(2)14.59%
Max EPS beat(2)394.12%
EPS beat(4)4
Avg EPS beat(4)173.94%
Min EPS beat(4)14.59%
Max EPS beat(4)394.12%
EPS beat(8)7
Avg EPS beat(8)102.62%
EPS beat(12)10
Avg EPS beat(12)105.29%
EPS beat(16)13
Avg EPS beat(16)203.97%
Revenue beat(2)2
Avg Revenue beat(2)1.23%
Min Revenue beat(2)1.23%
Max Revenue beat(2)1.23%
Revenue beat(4)4
Avg Revenue beat(4)6.13%
Min Revenue beat(4)1.23%
Max Revenue beat(4)11.71%
Revenue beat(8)6
Avg Revenue beat(8)2.95%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)4.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-59.09%
EPS NY rev (1m)0%
EPS NY rev (3m)4.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.09 | ||
| Fwd PE | 18.18 | ||
| P/S | 1.27 | ||
| P/FCF | 6.82 | ||
| P/OCF | 6.8 | ||
| P/B | 2.88 | ||
| P/tB | 5.16 | ||
| EV/EBITDA | 3.65 |
EPS(TTM)0.74
EY12.35%
EPS(NY)0.33
Fwd EY5.5%
FCF(TTM)0.88
FCFY14.66%
OCF(TTM)0.88
OCFY14.7%
SpS4.73
BVpS2.08
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.86% | ||
| ROE | 46.27% | ||
| ROCE | 39.77% | ||
| ROIC | 31.42% | ||
| ROICexc | 183.86% | ||
| ROICexgc | N/A | ||
| OM | 19.35% | ||
| PM (TTM) | 20.35% | ||
| GM | 72.33% | ||
| FCFM | 18.58% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score6
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.01 | ||
| Debt/EBITDA | 0.19 | ||
| Cap/Depr | 1.04% | ||
| Cap/Sales | 0.05% | ||
| Interest Coverage | 5.43 | ||
| Cash Conversion | 77.32% | ||
| Profit Quality | 91.27% | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.62 | ||
| Altman-Z | -5.02 |
F-Score6
WACC9.56%
ROIC/WACC3.29
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.54%
EPS Next Y-17.31%
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
EPS Next 5Y-12.89%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%-32.3%
Revenue Next Year-3.32%
Revenue Next 2Y-3.85%
Revenue Next 3Y-2.82%
Revenue Next 5Y-1.09%
EBIT growth 1Y135.74%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year58.8%
EBIT Next 3Y9.99%
EBIT Next 5YN/A
FCF growth 1Y291%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y43.58%
OCF growth 3Y23.52%
OCF growth 5Y11.7%
PUMA BIOTECHNOLOGY INC / PBYI FAQ
Can you provide the ChartMill fundamental rating for PUMA BIOTECHNOLOGY INC?
ChartMill assigns a fundamental rating of 5 / 10 to PBYI.
Can you provide the valuation status for PUMA BIOTECHNOLOGY INC?
ChartMill assigns a valuation rating of 7 / 10 to PUMA BIOTECHNOLOGY INC (PBYI). This can be considered as Undervalued.
What is the profitability of PBYI stock?
PUMA BIOTECHNOLOGY INC (PBYI) has a profitability rating of 8 / 10.
What are the PE and PB ratios of PUMA BIOTECHNOLOGY INC (PBYI) stock?
The Price/Earnings (PE) ratio for PUMA BIOTECHNOLOGY INC (PBYI) is 8.09 and the Price/Book (PB) ratio is 2.88.
What is the financial health of PUMA BIOTECHNOLOGY INC (PBYI) stock?
The financial health rating of PUMA BIOTECHNOLOGY INC (PBYI) is 5 / 10.